Arkolith/Insider Trading/ABOS/Form 4

OConnell Daniel Joseph

Chief Executive Officer, DirectorAcumen Pharmaceuticals, Inc. (ABOS) · full profile →Form 4 · filed Jan 12, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$47K
Net Open-Market Flow
-$47K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Sell(S)5K$1.73$9K594K
Jan 9, 2026Sell(S)13K$1.76$23K599K
Jan 8, 2026Sell(S)8K$1.82$15K612K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-001895) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML